Aquestive Therapeutics’ Anaphylm AQST-109 epinephrine sublingual film demonstrated durability despite testing in extreme ...

The company has filed a Drug Master File (DMF) with the U.S. Food and Drug Administration (FDA) — a critical regulatory step. This product is now ready to be converted into a finished drug product.

The FDA has approved neffy 1 mg epinephrine nasal spray for treating anaphylaxis and other type 1 allergic reactions in ...

This product is now ready to be converted into a finished drug product. The entirety of the Epinephrine API manufacturing campaign has been performed in the United States, further reinforcing ...

Validation Completed for a Novel, Cost-Competitive Epinephrine Active Pharmaceutical Ingredient Process, Drug Master File Successfully Filed Richmond, Virginia, March 17, 2025 (GLOBE NEWSWIRE) -- ...

Neffy (epinephrine nasal spray) 1mg is approved for the emergency treatment of type 1 allergic reactions in children aged 4 ...

The global epinephrine auto-injector market is set for steady expansion, driven by the increasing prevalence of severe allergies worldwide. According to market projections, global sales of epinephrine ...

Parents and pediatricians just gained one more tool to combat severe allergic reactions in young kids. San Diego-based ARS ...

Neffy 1 mg is the “first significant innovation” for epinephrine delivery in small children aged 4 years and up in over 35 ...

The FDA has approved Neffy, a needle-free nasal spray, for children aged 4 and up, providing fast and effective treatment for severe allergic reactions and anaphylaxis.